A 12-Week Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants with Mild-to-Moderate Alzheimer’s Disease (AD). Buntanetap will be provided in the form of an oral capsule. Relevant Inclusion Criteria:

• Diagnosis of AD
• Age 55-85
• MMSE 14-24
• Have a reliable study partner who will attend all study visits with the participant

Relevant Exclusion Criteria:

• History of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression
• Non-AD Dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, Parkinson’s disease dementia, or B12 and thyroid deficiency-caused dementia
• History of seizure disorder (acceptable if on stable meds)
• Uncontrolled Type 1 or Type 2 diabetes
• Has cancer or has had a malignant tumor within the past year

Use of the following medications is allowed if participants have been stabilized for at least 4 weeks before screening and will continue to be stable throughout the study:

• Tricyclic antidepressants
• Antipsychotics prescribed for any reason (some exclusions apply)
• Psychostimulants